Aqemia pricing
Partnership announcements carry the figures: up to $140 million under the December 2023 Sanofi agreement, counting upfront and milestone payments Aqemia can earn rather than money received, and a further payment when Sanofi nominated a new target in July 2026. Partners pay for discovery programs rather than software, so no rate card or unit of charge exists.
How Aqemia pricing works
- Pricing model
- Negotiated collaboration. Revenue comes from multi year pharmaceutical research agreements paid through upfront payments, milestone payments triggered by target nominations and program stage gates, and royalties on any approved product, supplemented by equity funding and a France 2030 public award. No software is licensed and no subscription is offered.
- Implementation
- Not itemized. Partners receive designed molecules rather than software, and each collaboration runs as joint work between Aqemia's researchers and the partner's own scientists.
Aqemia pricing against its alternatives
Published prices for Aqemia and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- AAqemiaNo published price
- VValo HealthNo published price
- NNabla BioNo published price
- PPostEraNo published price
- IIktosNo published price
- GGenesis Molecular AINo published price
- MMolcureNo published price
- MMedvoltNo published price
- CCradleNo published price
Aqemia pricing, answered
How much does Aqemia cost?
Aqemia does not publish a price. Partnership announcements carry the figures: up to $140 million under the December 2023 Sanofi agreement, counting upfront and milestone payments Aqemia can earn rather than money received, and a further payment when Sanofi nominated a new target in July 2026. Partners pay for discovery programs rather than software, so no rate card or unit of charge exists.
Does Aqemia charge an implementation fee?
Not itemized. Partners receive designed molecules rather than software, and each collaboration runs as joint work between Aqemia's researchers and the partner's own scientists.